Skip to main content
CORIinactive

Corium International, Inc.

Biopharma developer (SEC filing verified)

CORI evidence brief

What we can confirm

BioSniper Score:
9.2 / 10
Lead Asset:
corplex donepezil (Phase 3)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 9.2 / 10 · Lead Asset: corplex donepezil (Phase 3)
BioSniper AIPage evidence connected

Prepared research question

What matters most for CORI—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

9.2/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

corplex donepezil (Phase 3)

Next Catalyst

—

Tracking 6 pipeline candidates for Corium International, Inc..

Similar companies

BIIBLNTHACADPRTAALECNMRA

Run Corium International, Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Corium International, Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth9.8

6 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company
923 companies304,846 SEC filings22,682 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.